Collplant issues letter to shareholders

Rehovot, israel, jan. 5, 2022 /prnewswire/ -- collplant biotechnologies (nasdaq: clgn), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its chief executive officer, yehiel tal, to its shareholders. view as pdf dear shareholders, 2021 has been a pivotal and productive year for collplant which resulted in several significant achievements.
CLGN Ratings Summary
CLGN Quant Ranking